Our Company
A new concept for the research antibody market:
Our mission is to eradicate wasted R&D expenses caused by poorly characterised, unstable, inconsistently performing, or no longer available immunological reagents. Among the large amounts of commercially available antibodies to any one specific protein/biomarker, we identify those few that meet the highest quality standards. The information on the manufacturer’s product sheet is thoroughly scrutinised. We use proprietary selection criteria, as outlined below, to identify the best candidate antibodies.
Based on this concept, we offer antibodies for sale and we offer custom services to select the right antibody from the market according to the customer’s specific requirements and under strict confidentiality.
Our Expertise
As far as we can see, our approach is nowhere else to be found. We are the first.
Our Aeonian Rating® sets a new quality standard, reminiscent to the Michelin stars for restaurants. Our catalogue is defined by this standard.
Scientists and assay developers are going to save a fortune by not having to buy and try tens of different antibodies to the same protein. There is also the risk of buying the same antibody from different sources (Voskuil, 2014). Our unique approach allows the customer to take a precious short cut finding the right antibodies straight away based on specificity, selectivity and long-term availability without variations in performance.(See also What is the difference between antibody’s specificity and its selectivity).
We build our services on decades of experience in the antibody trade and industries and we know all major players and their products. This facilitates us identifying the actual manufacturers of the antibodies with the right characteristics required by the customer. In addition, we have equal length of experience in immunoassays and in their development. This knowledge helps us to understand the customer’s requirements even before we commence our hunt (See also Introduction to selectivity and integrity).
JLA Voskuil (2014) Commercial antibodies and their validation. F1000Research 3:232
Our Scope
Bringing together supply and demand of the highest quality antibodies and their derivatives, tailored to the requirements of research and of assay development.
Our Solution
What is the problem?
In recent years, more and more articles appeared to address the problems associated with poorly performing commercial antibodies. These problems do not only affect the scientists and their finance, they also affect the output of reliable science that is meant to provide solutions to human diseases. For each protein, there are many antibodies on the market and for the most popular proteins there could be well over 1000 antibody offerings. This complexity in the antibody market has not been exhaustively addressed in the past, and therefore we have addressed this by separating the performance-related data from the other parameters linked to each commercial antibody (Voskuil, 2017). This two-tier approach facilitates scientists to find their way in this highly complex market. Extra complications come from variations in batches and aliquots and from rebranding to feature the same product in many catalogues. Such complexities are not readily visible to the scientists who shop around to find a fit-for-purpose antibody.
How do we fix it?
We have carefully constructed a new catalogue to facilitate those scientists who struggle finding the right antibody from the market. In addition, we offer our expertise assistance in identifying the right product from elsewhere when we cannot make it available ourselves.
JLA Voskuil (2017) The challenges with the validation of research antibodies. F1000Research 2017, 6:161